Basilea Pharmaceutica AG Stock Xetra
Stocks
PK5
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 673M 838M 732M 627M 1.19B 79.77B 1.21B 8.08B 3.14B 39.21B 3.14B 3.08B 135B | P/E 2026 * |
14.4x | P/E 2027 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise Value | 521M 648M 567M 485M 921M 61.73B 935M 6.25B 2.43B 30.34B 2.43B 2.38B 105B | EV / Sales 2026 * |
1.98x | EV / Sales 2027 * | 1.72x |
| Free-Float |
91.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Basilea Pharmaceutica AG
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 2018-04-18 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 2019-04-09 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 2011-11-28 |
| Chairman | 71 | 2013-04-08 | |
Nicole Onetto
BRD | Director/Board Member | 72 | 2017-04-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 838M | |
| +1.70% | +7.41% | +3.12% | +8.46% | 49.92B | |
| +0.92% | +3.93% | +399.71% | +605.33% | 40.23B | |
| +1.89% | +8.32% | +26.06% | -6.35% | 34.55B | |
| +2.38% | +6.35% | +21.25% | +64.58% | 33.09B | |
| +3.96% | +10.67% | +11.89% | +38.86% | 27.51B | |
| +2.51% | +5.27% | - | - | 17.05B | |
| +2.58% | +5.79% | +73.44% | +133.27% | 15.92B | |
| +0.32% | +0.58% | +13.67% | +19.09% | 13.86B | |
| +3.30% | +0.76% | +90.23% | +99.12% | 13.52B | |
| Average | +1.96% | +5.82% | +79.92% | +120.30% | 27.3B | |
| Weighted average by Cap. | +2.06% | +6.53% | +90.75% | +137.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 263M 327M 286M 245M 465M 31.16B 472M 3.16B 1.23B 15.32B 1.23B 1.2B 52.78B | 267M 333M 291M 249M 473M 31.7B 480M 3.21B 1.25B 15.58B 1.25B 1.22B 53.69B |
| Net income | 51.57M 64.19M 56.11M 48.07M 91.17M 6.11B 92.55M 619M 241M 3B 241M 236M 10.35B | 39.24M 48.84M 42.7M 36.58M 69.37M 4.65B 70.43M 471M 183M 2.29B 183M 179M 7.88B |
| Net Debt | -152M -190M -166M -142M -269M -18.05B -273M -1.83B -711M -8.87B -711M -696M -30.57B | -213M -265M -231M -198M -376M -25.19B -382M -2.55B -992M -12.38B -993M -972M -42.68B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
